In 2023, Taiwan’s premature birth rate was 10.88%, meaning about one in 10 newborns was born before 37 weeks of gestation.

Despite near universal availability of nirsevimab, only 35% of eligible children receive nirsevimab for RSV prophylaxis.

Despite strong clinical data, RSV immunization rates among pregnant women and older adults remain worryingly low, ...

The risk for respiratory syncytial virus-related hospitalizations is elevated in children with chronic medical conditions ...

A single shot during pregnancy is proving to be a powerful shield for newborns against one of the most common and dangerous viruses for infants: RSV. In a new UK study, babies whose mothers received t ...

Infants, toddlers and preschoolers exhibit symptoms of long COVID, but the symptoms can be different and more difficult to ...

Palivizumab, when given through the veins or into a muscle (systemically), reduces hospitalisations due to respiratory syncytial virus (RSV) and reduces respiratory problems later on (chest wheezing), ...

The CDC recently updated RSV vaccine recommendations to include certain adults aged 50 and up. When is the best time to get ...

A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa’s private sector, but not yet in public clinics. The country’s advisory group on ...

The largest US real-world study of BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection successfully met both of its co-primary endpoints, demonstrating that BEYFORTUS provides protection for babies ...

The COVID booster currently available is based on the JN.1 subvariant. Nimbus is a direct descendant of JN.1 – as is another ...